Results 41 to 50 of about 111,529 (192)

Lipoprotein turnover and possible remnant accumulation in preeclampsia: insights from the Freiburg Preeclampsia H.E.L.P.-apheresis study

Lipids in Health and Disease, 2018
Background Preeclampsia is a life-threatening disease in pregnancy, and its complex pathomechanisms are poorly understood. In preeclampsia, lipid metabolism is substantially altered.
Christine Contini, Martin Jansen, Brigitte König, Filiz Markfeld-Erol, Mirjam Kunze, Stefan Zschiedrich, Ulrich Massing, Irmgard Merfort, Heinrich Prömpeler, Ulrich Pecks, Karl Winkler, Gerhard Pütz   +11 more
doaj   +1 more source

Pregnancy in a Woman with Homozygous Familial Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis

American Journal of Perinatology Reports, 2012
Pregnancy in women with homozygous familial hypercholesterolemia (FH) has been rarely reported and might pose risks on the mother and her fetus. Although most reported cases remained on low-density lipoprotein (LDL) apheresis, there are no clear ...
Akl C. Fahed, Anwar H. Nassar
doaj   +1 more source

Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives

MedComm, Volume 7, Issue 7, July 2026.
Schematic illustration of four emerging CRISPR–Cas delivery platforms defined by distinct design principles and structural features: virus‐mimicking nanosystems (e.g., VLPs), cell‐derived extracellular vesicles, cell‐penetrating peptides, and stimuli‐responsive scaffolds. These platforms enable spatiotemporally controlled delivery of RNPs, mRNA, or DNA
Meijia Yang, Yiqiong Song, Ziyang Wang, Ke Chao, Lifeng Li, Xu Zhang, Xiaoran Duan, Chenglong Yu, Ruyue Xue, Jie Zhao   +9 more
wiley   +1 more source

Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study.

, 2018
Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are last therapeutic resorts in patients with familial hypercholesterolemia (FH).
Karlsson, Helen, Ljunggren, Stefan A,, Marcusson-Ståhl, Maritha, Anders Hovland, Kjellmo, Christian Abendstein,, Cederbrant, Karin,, Mathisen, Monica,, Cederbrant, Karin, Mathisen, Monica, Lappegård, Knut Tore, Lappegård, Knut Tore,, Kjellmo, Christian Abendstein, Christian Abendstein Kjellmo, Maritha Marcusson-Ståhl, Marcusson-Ståhl, Maritha,, Knut Tore Lappegård, Stefan Ljunggren, Karin Cederbrant, Hovland, Anders, Helen Karlsson, Monica Mathisen, Karlsson, Helen,, Ljunggren, Stefan A, Hovland, Anders,   +23 more
core   +1 more source

Lipoprotein apheresis to treat elevated lipoprotein (a)1

Journal of Lipid Research, 2016
An elevated plasma concentration of lipoprotein (a) [Lp(a)] is an independent risk factor for cardiovascular disease. Life style modification and currently available drugs either fail to effectively lower plasma Lp(a) levels or do not result in clinical ...
Elisa Waldmann, Klaus G. Parhofer
doaj   +1 more source

Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia[S]

Journal of Lipid Research, 2014
Lipoprotein-apheresis (apheresis) removes LDL-cholesterol in patients with severe dyslipidemia. However, reduction is transient, indicating that the long-term cardiovascular benefits of apheresis may not solely be due to LDL removal. Microparticles (MPs)
Katherine D. Connolly, Gareth R. Willis, Dev B.N. Datta, Elizabeth A. Ellins, Kristin Ladell, David A. Price, Irina A. Guschina, D. Aled Rees, Philip E. James   +8 more
doaj   +1 more source

Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a)

Antioxidants, 2021
Aims: An abundance of epidemiological evidence demonstrates that elevated lipoprotein(a) (Lp(a)) represents a significant contributing risk factor towards the development of cardiovascular disease.
Tina Z. Khan, Adam Hartley, Dorian Haskard, Mikhail Caga-Anan, Dudley J. Pennell, Peter Collins, Mahmoud Barbir, Ramzi Khamis   +7 more
doaj   +1 more source

Homozygous familial hypercholesterolemia with stenosis of the left anterior descending coronary artery successfully treated with weekly low‐density lipoprotein apheresis for 16 years without percutaneous coronary intervention

Clinical Case Reports, 2019
We successfully treated a patient with homozygous familial hypercholesterolemia (HoFH) with stable coronary arterial disease using optimal medical therapy and low‐density lipoprotein (LDL) apheresis for 16 years without percutaneous coronary intervention
Takanori Yasu, Masahiro Shimoyama, Hiroshi Wada, Tomohiro Iwakura, Shigeru Toyoda, Atsuhiko Kawabe, Takushi Sugiyama   +6 more
doaj   +1 more source

Role of Plasmalogens in the Enhanced Resistance of LDL to Copper-Induced Oxidation After LDL Apheresis

, 1999
—Extracorporeal reduction of plasma low density lipoproteins (LDLs) by LDL apheresis was shown to attenuate the proatherogenic influences of LDL, such as impairment of vasodilation and increased monocyte adhesion to the endothelium.
Thorolf Brosche, Bernd Engelmann, Daniela Hahnel, Joachim Thiery   +3 more
core   +1 more source

Successful Treatment Of Homozygous Familial Hypercholesterolemia Using Cascade Filtration Plasmapheresis

Turkish Journal of Hematology, 2012
OBJECTIVE: The aim of our study is to discuss the efficacy of low-density lipoprotein-cholesterol (LDL-C) apheresis procedure using the cascade filtration system for pediatric patients with homozygous familial hypercholesterolemia (FH), and to clarify ...
Fatih Kardas, Aysun Cetin, Musa Solmaz, Ruksan Buyukoglan, Leylagul Kaynar, Mustafa Kendirci, Bulent Eser, Ali Unal   +7 more
doaj   +1 more source